<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0 0 0 0.25in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<HR NOSHADE SIZE="3" STYLE="color: Black; width: 100%; margin-top: 3pt; margin-bottom: 3pt">
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>UNITED STATES</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>SECURITIES AND EXCHANGE COMMISSION</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>WASHINGTON, D.C. 20549</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 18pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>FORM 8-K</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>CURRENT REPORT</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Pursuant to Section&nbsp;13 or 15(d)
of the</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Securities Exchange Act of 1934</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Date of report (Date of earliest event reported):
August 7, 2012 (August 3, 2012)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 18pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><U>AVRA Surgical Robotics, Inc.</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>(Exact name of registrant as specified
in Charter)</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 30%; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Delaware</TD>
    <TD STYLE="width: 2%; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="width: 36%; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">000-52330</TD>
    <TD STYLE="width: 2%; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="width: 30%; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">32-2277305</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: center">(State or other jurisdiction of incorporation)</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">(Commission File No.)</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">(IRS Employer Identification No.)</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><U>c/o Stamell &amp; Schager, LLP, 1
Liberty Plaza 35<SUP>th</SUP> Floor, New York, NY 10006</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0.5in">(Address of Principal
Executive Offices)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><U>(212) 566-4047</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0.5in">(Registrant&rsquo;s
telephone number, including area code)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><U>RFG Acquisition II Inc.</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0.5in">(Former name or former
address, if changed since last report)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Check the appropriate box below if the Form 8-K filing is intended
to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction
A.2. below):</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 4%; font-family: Wingdings">&uml;</TD>
    <TD STYLE="width: 96%">Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 4%; font-family: Wingdings">&uml;</TD>
    <TD STYLE="width: 96%">Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 4%; font-family: Wingdings">&uml;</TD>
    <TD STYLE="width: 96%">Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 4%; font-family: Wingdings">&uml;</TD>
    <TD STYLE="width: 96%">Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Rule-Page --><DIV ALIGN="LEFT" STYLE="margin-top: 3pt; margin-bottom: 3pt"><DIV STYLE="font-size: 1pt; border-top: Black 2pt solid; width: 100%">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 9%; font-weight: bold">Item 1.01</TD>
    <TD STYLE="width: 91%; font-weight: bold">Entry into a Material Definitive Agreement.</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">AVRA Surgical Robotics,
Inc. (formerly RFG Acquisition II, Inc.)(the &quot;Company&quot;) entered into an employment agreement, dated August 2, 2012, with
Stephan Sagolla (the &quot;Employment Agreement&quot;) in connection with the Company's new business plan to commence operations
in the business of designing, developing, and manufacturing surgical robotic systems.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Under the terms and
conditions of the Employment Agreement, the Company agrees to employ Mr. Sagolla as the Chief Executive Officer of the Company,
for a term of five (5) years unless earlier terminated pursuant to the terms therein. Mr. Sagolla will receive an annual base salary
of &euro;300,000, subject to annual review and increases by the Company's board of directors, as it deems appropriate. His base
salary will be paid monthly on the last day of each month. In addition to his base salary, the Company has agreed to pay the following
expenses: (i) &euro;15,000, paid monthly at the end of each month, in full compensation for any Social Security assessments, health
insurance and any analogous charges assessed based on income; (ii) &euro;48,000, paid at the end of each calendar year, into a
private pension fund for Mr. Sagolla's benefit; (iii) all leasing and operating costs arising from Mr. Sagolla's use of the Company's
car; (iv) four weeks of paid vacation time per year; (v) continued base salary for up to twelve months of disability; (vi) severance
pay for six months at the base salary rate, plus accrued benefits, including all vested stock options in the event that he is terminated
by the Company during the first two years of his employment; (vii) executive compensation in the form of options or shares, or
both, under any long-term equity compensation plan that may be adopted by the Company; and (viii) other business expenses reasonably
incurred for promoting the Company's business. Upon any termination, Mr. Sagolla will be entitled to unpaid accrued salary and
benefits as of the termination date. If Mr. Sagolla chooses to resign and, thus, terminate his employment with the Company, he
will not own, manage or control any business that directly competes with the Company, its subsidiaries or affiliates for the two-year
period thereafter; however, if the Company terminates his employment, the non-compete period will be co-extensive with the number
of months for which Mr. Sagolla would be entitled to severance pay.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">A form of the Employment Agreement is filed
with this report as Exhibit 10.1 and is incorporated by reference herein.&nbsp;&nbsp;The foregoing descriptions of the Employment
Agreement do not purport to be complete and are qualified entirely by reference to the full text of the Employment Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 9%; font-weight: bold">Item 5.02</TD>
    <TD STYLE="width: 91%; font-weight: bold">Departure of Directors or Certain Officers; Election of Directors; Appointment of Principal Officers.</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">On August 3, 2012, our Board of Directors
(the &quot;Board&quot;) appointed Stephan Sagolla, age 59, to serve as the Chief Executive Officer of the Company and Bernd Gombert,
age 52, to serve as the Chief Scientist and Technical Officer of the Company, effective as of August 3, 2012.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The biographies of our new officers are as
follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><B>Stephan Sagolla, 59,</B> the
Company&rsquo;s Chief Executive Officer since August 2, 2012, served as the Global CEO of Berchtold Group, a leading supplier of
operating room equipment and consulting services from April 2009 to December 2011. Between April 2005 and March 2009, Mr. Sagolla
was CEO, Managing Director and Executive Director of Vanguard AG, SteriPlus, Vanguard Medical Services, and Vanguard Iberica, as
well as Director of their Business Development for China. He also served as President and CEO Interton USA and Managing Director
of Interton International Group from January 2002 to March 2005. The Company believes that Mr. Sagolla&rsquo;s experience with
managing companies and sales in the medical devices and services industry will be an asset to the Company as it seeks to commence
operations in the surgical robotics business.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><B>Bernd Gombert, 52, </B>the
Company&rsquo;s Chief Scientist and Technical Officer since August 2, 2012, has founded companies such as LogiCad 3D GmbH (now
a subsidiary of the global company Logitech), eStop GmbH (which develops forward-looking brake technologies), as well as the AVRA
Medical Technology Center. From approximately 1990 to 2001, he served as head of development at the Institute of Robotics and Mechatronics
at German Aerospace, where he was responsible for developments in robotics, power transmission and in medical technology. Mr. Gombert
also has approximately 180 international patents and 120 scientific papers as well as numerous awards including the Hermes award,
the Rudolf Diesel gold medal and the Federal Cross of Merit with Ribbon of the Federal Republic of Germany for his outstanding
engineering achievements. The Company believes that Mr. Gombert&rsquo;s experience as a developer and businessman in the mechatronics
and innovative systems industry will be beneficial to the Company as it seeks to develop its surgical robotics business.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The information set forth in Item 1.01 of
this Current Report on Form 8-K is hereby incorporated into this Item 5.02 by reference.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 9%; font-weight: bold">Item 5.03</TD>
    <TD STYLE="width: 91%; font-weight: bold">Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year.</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">We changed our name to &ldquo;AVRA Surigical
Robotics, Inc.&rdquo; by filing a Certificate of Ownership and Merger with the Office of Secretary of State of Delaware on August
3, 2012. The name change was effected by merging AVRA Surgical Robotics, Inc., our wholly owned subsidiary, with and into the registrant,
pursuant to which the Company survived but adopted the name of the subsidiary. The merger and the resulting change of our name
were approved by the unanimous written consent of our Board on August 3, 2012.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in"><FONT STYLE="background-color: yellow"></FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 9%; font-weight: bold">Item 5.06</TD>
    <TD STYLE="width: 91%; font-weight: bold">Change in Shell Company Status.</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Effective upon the
appointments of Stephan Sagolla and Bernd Gombert, the Company has determined to commence operations in the business of designing,
developing and manufacturing surgical robotic systems either through a potential business combination in this industry or by entering
into a joint development agreement with another entity in this industry. In furtherance of this new business, the Company has appointed
new management, entered into an employment agreement and changed its name, each as more specifically described in Items 1.01 and
5.03, respectively, which are incorporated by reference herein. As a result of the foregoing actions, we have commenced operations
as a surgical robotics business and, therefore, no longer constitute a shell company as defined in Rule 12b-2 under the Exchange
Act.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 9%; font-weight: bold">Item 9.01</TD>
    <TD STYLE="width: 91%; font-weight: bold">Financial Statement and Exhibits.</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-size: 10pt"><B>(d)</B></FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt"><B>Exhibits</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 10%; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Exhibit No.</TD>
    <TD STYLE="width: 2%; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="width: 88%; font-weight: bold; border-bottom: Black 1pt solid">Description</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: center">3.1</TD>
    <TD>&nbsp;</TD>
    <TD>Certificate of Ownership and Merger filed with the&nbsp;Office of Secretary of State of Delaware&nbsp;on August 3, 2012</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: center">10.1</TD>
    <TD>&nbsp;</TD>
    <TD>Form of Employment Agreement with Stephan Sogalla, dated August 2, 2012</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<!-- Field: Page; Sequence: 3 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>SIGNATURES</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Pursuant to the requirements of the Securities
Exchange Act of 1934, as amended, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto
duly authorized.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold">AVRA SURGICAL ROBOTICS, INC.</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 50%">&nbsp;</TD>
    <TD STYLE="width: 5%">&nbsp;</TD>
    <TD STYLE="width: 45%">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>Date:&nbsp;August 7, 2012</TD>
    <TD>By:&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid">/s/ Barry F. Cohen</TD></TR>
<TR STYLE="vertical-align: top">
    <TD COLSPAN="2">&nbsp;</TD>
    <TD>Barry F. Cohen, President</TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 4; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

</BODY>
</HTML>
[{"type": "8-K", "sequence": "1", "filename": "v320625_8k.htm", "description": "8-K", "secsgml_size_bytes": 23292}]
{"company-data": {"conformed-name": "AVRA Surgical Robotics, Inc.", "cik": "0001377040", "assigned-sic": "6770", "irs-number": "000000000", "fiscal-year-end": "1231"}, "filing-values": {"form-type": "8-K", "act": "34", "file-number": "000-52330", "film-number": "121014506"}, "business-address": {"street1": "C/O GRANITE INVESTOR GROUP, INC.", "street2": "ONE LIBERTY PLAZA, 35TH FLOOR", "city": "NEW YORK", "state": "NY", "zip": "10006", "phone": "212-566-4051"}, "mail-address": {"street1": "C/O GRANITE INVESTOR GROUP, INC.", "street2": "ONE LIBERTY PLAZA, 35TH FLOOR", "city": "NEW YORK", "state": "NY", "zip": "10006"}, "former-company": [{"former-conformed-name": "RFG Acquisition II Inc.", "date-changed": "20061127"}, {"former-conformed-name": "RFG ACQUISTION II INC", "date-changed": "20060929"}]}
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d)
of the
Securities Exchange Act of 1934
Date of report (Date of earliest event reported):
August 7, 2012 (August 3, 2012)
AVRA Surgical Robotics, Inc.
(Exact name of registrant as specified
in Charter)
Delaware
000-52330
32-2277305
(State or other jurisdiction of incorporation)
(Commission File No.)
(IRS Employer Identification No.)
c/o Stamell & Schager, LLP, 1
Liberty Plaza 35
th
Floor, New York, NY 10006
(Address of Principal
Executive Offices)
(212) 566-4047
(Registrant's
telephone number, including area code)
RFG Acquisition II Inc.
(Former name or former
address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended
to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction
A.2. below):
¨
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
¨
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
¨
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
¨
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Item 1.01
Entry into a Material Definitive Agreement.
AVRA Surgical Robotics,
Inc. (formerly RFG Acquisition II, Inc.)(the "Company") entered into an employment agreement, dated August 2, 2012, with
Stephan Sagolla (the "Employment Agreement") in connection with the Company's new business plan to commence operations
in the business of designing, developing, and manufacturing surgical robotic systems.
Under the terms and
conditions of the Employment Agreement, the Company agrees to employ Mr. Sagolla as the Chief Executive Officer of the Company,
for a term of five (5) years unless earlier terminated pursuant to the terms therein. Mr. Sagolla will receive an annual base salary
of €300,000, subject to annual review and increases by the Company's board of directors, as it deems appropriate. His base
salary will be paid monthly on the last day of each month. In addition to his base salary, the Company has agreed to pay the following
expenses: (i) €15,000, paid monthly at the end of each month, in full compensation for any Social Security assessments, health
insurance and any analogous charges assessed based on income; (ii) €48,000, paid at the end of each calendar year, into a
private pension fund for Mr. Sagolla's benefit; (iii) all leasing and operating costs arising from Mr. Sagolla's use of the Company's
car; (iv) four weeks of paid vacation time per year; (v) continued base salary for up to twelve months of disability; (vi) severance
pay for six months at the base salary rate, plus accrued benefits, including all vested stock options in the event that he is terminated
by the Company during the first two years of his employment; (vii) executive compensation in the form of options or shares, or
both, under any long-term equity compensation plan that may be adopted by the Company; and (viii) other business expenses reasonably
incurred for promoting the Company's business. Upon any termination, Mr. Sagolla will be entitled to unpaid accrued salary and
benefits as of the termination date. If Mr. Sagolla chooses to resign and, thus, terminate his employment with the Company, he
will not own, manage or control any business that directly competes with the Company, its subsidiaries or affiliates for the two-year
period thereafter; however, if the Company terminates his employment, the non-compete period will be co-extensive with the number
of months for which Mr. Sagolla would be entitled to severance pay.
A form of the Employment Agreement is filed
with this report as Exhibit 10.1 and is incorporated by reference herein.  The foregoing descriptions of the Employment
Agreement do not purport to be complete and are qualified entirely by reference to the full text of the Employment Agreement.
Item 5.02
Departure of Directors or Certain Officers; Election of Directors; Appointment of Principal Officers.
On August 3, 2012, our Board of Directors
(the "Board") appointed Stephan Sagolla, age 59, to serve as the Chief Executive Officer of the Company and Bernd Gombert,
age 52, to serve as the Chief Scientist and Technical Officer of the Company, effective as of August 3, 2012.
The biographies of our new officers are as
follows:
Stephan Sagolla, 59,
the
Company's Chief Executive Officer since August 2, 2012, served as the Global CEO of Berchtold Group, a leading supplier of
operating room equipment and consulting services from April 2009 to December 2011. Between April 2005 and March 2009, Mr. Sagolla
was CEO, Managing Director and Executive Director of Vanguard AG, SteriPlus, Vanguard Medical Services, and Vanguard Iberica, as
well as Director of their Business Development for China. He also served as President and CEO Interton USA and Managing Director
of Interton International Group from January 2002 to March 2005. The Company believes that Mr. Sagolla's experience with
managing companies and sales in the medical devices and services industry will be an asset to the Company as it seeks to commence
operations in the surgical robotics business.
Bernd Gombert, 52,
the
Company's Chief Scientist and Technical Officer since August 2, 2012, has founded companies such as LogiCad 3D GmbH (now
a subsidiary of the global company Logitech), eStop GmbH (which develops forward-looking brake technologies), as well as the AVRA
Medical Technology Center. From approximately 1990 to 2001, he served as head of development at the Institute of Robotics and Mechatronics
at German Aerospace, where he was responsible for developments in robotics, power transmission and in medical technology. Mr. Gombert
also has approximately 180 international patents and 120 scientific papers as well as numerous awards including the Hermes award,
the Rudolf Diesel gold medal and the Federal Cross of Merit with Ribbon of the Federal Republic of Germany for his outstanding
engineering achievements. The Company believes that Mr. Gombert's experience as a developer and businessman in the mechatronics
and innovative systems industry will be beneficial to the Company as it seeks to develop its surgical robotics business.
The information set forth in Item 1.01 of
this Current Report on Form 8-K is hereby incorporated into this Item 5.02 by reference.
Item 5.03
Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year.
We changed our name to "AVRA Surigical
Robotics, Inc." by filing a Certificate of Ownership and Merger with the Office of Secretary of State of Delaware on August
3, 2012. The name change was effected by merging AVRA Surgical Robotics, Inc., our wholly owned subsidiary, with and into the registrant,
pursuant to which the Company survived but adopted the name of the subsidiary. The merger and the resulting change of our name
were approved by the unanimous written consent of our Board on August 3, 2012.
Item 5.06
Change in Shell Company Status.
Effective upon the
appointments of Stephan Sagolla and Bernd Gombert, the Company has determined to commence operations in the business of designing,
developing and manufacturing surgical robotic systems either through a potential business combination in this industry or by entering
into a joint development agreement with another entity in this industry. In furtherance of this new business, the Company has appointed
new management, entered into an employment agreement and changed its name, each as more specifically described in Items 1.01 and
5.03, respectively, which are incorporated by reference herein. As a result of the foregoing actions, we have commenced operations
as a surgical robotics business and, therefore, no longer constitute a shell company as defined in Rule 12b-2 under the Exchange
Act.
Item 9.01
Financial Statement and Exhibits.
(d)
Exhibits
Exhibit No.
Description
3.1
Certificate of Ownership and Merger filed with the Office of Secretary of State of Delaware on August 3, 2012
10.1
Form of Employment Agreement with Stephan Sogalla, dated August 2, 2012
SIGNATURES
Pursuant to the requirements of the Securities
Exchange Act of 1934, as amended, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto
duly authorized.
AVRA SURGICAL ROBOTICS, INC.
Date: August 7, 2012
By:
/s/ Barry F. Cohen
Barry F. Cohen, President